PHARMACLINIX LIMITED

Financial Health Score: C+ (Fair but Declining)

While the company is not in immediate critical condition, it is exhibiting a chronic, persistent illness that requires intervention. The patient has a strong immune system (cash reserves) and no life-threatening debt, but it has been steadily losing body mass (equity) for several years. Without treatment, this downward trajectory will eventually lead to a weakened state.

1. Key Vital Signs

• Net Assets (Body Mass): £165,618 (2025)
  • Interpretation: This is the company's net worth. While still positive, it has dropped significantly from a peak of £299,115 in 2022. This represents a loss of over £133,000 in net worth over three years—a 44% reduction in the company's "body mass."
• Current Ratio (Circulatory Health): 4.46x
  • Calculation: Current Assets (£200,143) / Current Liabilities (£44,796).
  • Interpretation: This is a very healthy pulse. The company has £4.46 in short-term assets for every £1 of short-term debt. It can easily pay its immediate bills, meaning there is no risk of a sudden "heart attack" (insolvency).
• Liabilities (Blood Pressure): £44,796 (Up 106% from 2024)
  • Interpretation: Short-term creditors have more than doubled in a single year. This is a spike in blood pressure. While the company can currently handle this pressure, the rapid increase suggests the business is stretching supplier payments to conserve cash or is taking on more trade credit to fund operations.
• Fixed Assets (Bone Density): £10,271 (Up from £6,560)
  • Interpretation: A slight increase in long-term assets suggests minor capital investment, but the asset base remains very small, which is typical for a wholesale/cosmetics operation relying on stock and cash rather than heavy machinery.

2. Symptoms Analysis

The financial data reveals a clear discrepancy between the company's structural strength and its operational performance:

• Chronic Weight Loss: The most alarming symptom is the consistent year-on-year erosion of Shareholders' Funds. The business has shrunk from a net worth of nearly £300k to £165k. This indicates that the business is either trading at a loss (revenue not covering expenses) or the owners are extracting more cash than the business is generating.
• Rising Short-Term Pressure: The doubling of "Creditors due within one year" suggests the company is relying more heavily on supplier credit to keep the business running. This is a common tactic when cash flow tightens.
• Depleting Cash Reserves: Current assets dropped by £28,145 (from £228,288 to £200,143). The "cash in the veins" is reducing, which limits the company's ability to respond to emergencies or seize new opportunities.

3. Diagnosis

Diagnosis: Chronic Equity Erosion with Stable Short-Term Liquidity.

Pharmaclinix Ltd is a solvent business that is currently "bleeding out" equity. The patient is not in the emergency room—there are sufficient liquid assets to cover all immediate debts, and there are no long-term loans weighing the company down. However, the sustained loss of net assets over three consecutive years suggests a fundamental issue with the business model's profitability or the owners' withdrawal strategy.

Because the company files as a "Micro-entity," we cannot see the Profit & Loss account directly. However, the balance sheet shrinkage strongly implies that the business is generating insufficient profit to cover its operational costs and director drawings, or it is paying out dividends based on historical reserves rather than current profits.

4. Recommendations

To restore the patient to full health and stop the deterioration, the following interventions are recommended:

1. Stop the Bleeding (Profitability Review): Conduct an immediate review of gross margins. In the wholesale cosmetics industry, stock purchase costs must be tightly controlled. Verify that pricing strategies are covering all overheads.
2. Monitor Blood Pressure (Creditor Management): The doubling of trade creditors is a warning sign. Avoid stretching supplier payments further, as this can damage supplier relationships and restrict access to the stock (inventory) the business needs to sell.
3. Nutritional Support (Cash Flow Preservation): If the equity erosion is due to excessive director drawings or dividends, these must be reduced to match actual profitability. The business cannot sustain drawing down on its historical reserves indefinitely.
4. Fitness Regime (Debtor Collection): Ensure that any money owed to the business is collected promptly. Accelerating cash inflows will help offset the rise in liabilities and keep the circulatory system healthy.